Pay in 4 interest-free payments of $7.17 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Research goals: Metabolic & Weight Description Retatrutide (development code LY3437943) is a synthetic, once-weekly triple agonist of the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors that has been the subject of peer-reviewed phase 1 and phase 2 randomized controlled trials published in The New England Journal of Medicine , The Lancet , and Nature Medicine , including investigations of body weight, glycemic control, and hepatic steatosis in adult human participants
Cho et al., 2019)
The risk of bacterial contamination and peptide degradation increases significantly with age
GLP-1 patients represent a growing indication: localised residual fat following medical weight loss responds well to injectable fat dissolving, particularly Aqualyx
The impact of retatrutide on cardiovascular disease Retatrutide doesnt have an equivalent cardiovascular outcomes trial yet
Because the medication can make you feel fuller faster, youll likely eat smaller portions, which means you want to get the most bang for your buck in terms of nutrition
US$ 22.11
US$ 21.70
US$ 20.94
US$ 21.76
US$ 23.95
